 |
David de Gijsel, MD, MSc, MPH, works on the intersection of poverty and health. Currently, he focuses on the infectious complications of injection drug use, specifically on new care models for the integrated treatment of hepatitis C in people who inject drugs and for harm-reduction focused substance use disorder treatments.
David hails from the Netherlands, where he completed medical school at the University of Amsterdam. He completed his residency in Internal Medicine and Primary Care at Montefiore Medical Center/Albert Einstein College of Medicine in the Bronx, NY. He stayed at Montefiore as an internist for several years before spending two years in Kigali, Rwanda, teaching Rwandan medical students and residents through the Human Resources for Health Program. Upon his return to the US, he came to Dartmouth-Hitchcock for a fellowship in Infectious Disease and a residency in Leadership Preventive Medicine, combined with an MPH at The Dartmouth Institute.
David holds appointments as Assistant Professor at the Geisel School of Medicine and at The Dartmouth Institute for Health Policy & Clinical Practice. He is a staff physician in the Section of Infectious Disease & International Health at Dartmouth Hitchcock. He is the Chief Health Officer at Better Life Partners, a community-based substance use treatment program.
|
 |
Brock Christensen, PhD, received his B.S. from the University of Wisconsin Madison in Medical Microbiology & Immunology and French in 2002, and his PhD from the Program in Biological Sciences in Public Health at Harvard University in 2008. He trained as a postdoctoral research associate in molecular epidemiology of cancer at Brown University in the Department of Pathology and Laboratory Medicine. Dr. Christensen joined the faculty at Dartmouth in 2011. Is a Professor in the Departments of Community and Family Medicine in the Section of Biostatistics and Epidemiology, and Pharmacology and Toxicology.
Dr. Christensen's research is focused on combining advances in molecular biology, genomics and bioinformatics with the powerful techniques of modern epidemiology and statistics to characterize epigenetic states in human health and disease. His interests include understanding relationships between epigenetic states and exposures in the context of disease susceptibility, occurrence, and progression. By investigating complex interactions between the environment and somatic epigenetic alterations in target tissues, as well as epigenetic susceptibility traits in surrogate tissues, he hopes to develop their potential translational utility for diagnostic, prognostic, and/or treatment purposes.
|